

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
10518788

In re application of

Docket No: Q83533

Masakazu SATO, *et al.*National Stage Application of
PCT/JP03/10160
-filed August 8, 2003

Confirmation No.: Not Yet Assigned

Group Art Unit: Not Yet Assigned

Filed: December 21, 2004

Examiner: Not Yet Assigned

For: ARYL 5-THIO- β -D-GLUCOPYRANOSIDE DERIVATIVES AND THERAPEUTIC
AGENTS FOR DIABETES CONTAINING THE SAME**INFORMATION DISCLOSURE STATEMENT**
UNDER 37 C.F.R. §§ 1.97 and 1.98Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached PTO/SB/08 A & B (modified) form and/or listed herein and which the Examiner may deem material to patentability of the claims of the above-identified application.

One copy of each of the listed documents is submitted herewith, except for the following: U.S. patents and/or U.S. patent publications; and co-pending non-provisional U.S. applications filed after June 30, 2003.

DTO c'd PCT/PTO 21 DEC 2004

Q83533

10/518788

National Stage Application of
PCT/JP03/10160
-filed August 8, 2003


WO 03/000712 is cited in the last paragraph of page 2 of the subject application. EP 1 405 859 is a corresponding application and is submitted as a concise statement of relevance of WO 03/000712.

The present Information Disclosure Statement is being filed: (1) No later than three months from the application's filing date; (2) Before the mailing date of the first Office Action on the merits (whichever is later); or (3) Before the mailing date of the first Office Action after filing a request for continued examination (RCE) under §1.114, and therefore, no Statement under 37 C.F.R. § 1.97(e) or fee under 37 C.F.R. § 1.17(p) is required.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant does not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account.

Respectfully submitted,



Susan J. Mack
Registration No. 30,951

SUGHRUE MION, PLLC
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

WASHINGTON OFFICE
23373
CUSTOMER NUMBER

Date: December 21, 2004

Substitute for Form 1449 A & B/PTO		DT09	PTO/1449 21 DEC 2004
<u>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</u>		Application Number	National Stage Application of PCT/JP03/10150 -filed August 5, 2003 107518788
		Confirmation Number	Not Yet Assigned
		Filing Date	December 13, 2004
		First Named Inventor	Masakazu SATO
		Art Unit	Not Yet Assigned
		Examiner Name	Not Yet Assigned
Sheet	1	of	1
		Attorney Docket Number	Q83533

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

NON PATENT LITERATURE DOCUMENTS

Examiner Signature _____ **Date Considered** _____

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or in the comment box of this document. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to indicate here if English language Translation is attached.